Clinical Trials
76 trialsA Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
City of Hope Medical Center
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
City of Hope Medical Center
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
City of Hope Medical Center
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine
University of Arizona
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
Incyte Corporation
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
University of Wisconsin, Madison
Haplo Peripheral Blood Sct In GVHD Prevention
Massachusetts General Hospital
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Therapeutic Advances in Childhood Leukemia Consortium
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
City of Hope Medical Center
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Reduced Intensity Conditioning With Clofarabine, Antithymocyte Globulin (ATG), Total Lymphoid Irradiation (TLI) Followed by Allogeneic Stem Cell Transplant
Beth Israel Deaconess Medical Center
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Case Comprehensive Cancer Center
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
H. Lee Moffitt Cancer Center and Research Institute
MK-3475-013
Merck Sharp & Dohme LLC
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
National Cancer Institute (NCI)
VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies
Icahn School of Medicine at Mount Sinai
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
USBTXA127CBT
Tarix Pharmaceuticals
Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies
Bellicum Pharmaceuticals
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
University of Pennsylvania
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer
Jonsson Comprehensive Cancer Center
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
Case Comprehensive Cancer Center
Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies
Celgene
NK Cells in Cord Blood Transplantation
M.D. Anderson Cancer Center
Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer
University of Wisconsin, Madison
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
University of Maryland, Baltimore
Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation
Masonic Cancer Center, University of Minnesota
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
M.D. Anderson Cancer Center
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT
Stanford University
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia
Wake Forest University Health Sciences
T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer
Masonic Cancer Center, University of Minnesota
Low-Dose Fludarabine, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
California Cancer Consortium
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
University of Louisville
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
M.D. Anderson Cancer Center
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Dana-Farber Cancer Institute
506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
Alliance for Clinical Trials in Oncology
Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms
Celgene
Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy
University Health Network, Toronto
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
National Cancer Institute (NCI)
EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer
Indiana University
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
Indiana University
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
Duke University